The objectives of these guidelines are to provide evidence-based guidance on the use of thermal ablation to treat cervical precancer; and to support countries to update their national guidelines for the use of thermal ablation for cervical precancer....
Al-Mandeel, H. M;
Sagr, E;
Sait, K;
Latifah, H. M;
Al-Obaid, A;
Al-Badawi, I. A;
Alkushi, A. O;
Salem, H;
Massoudi, N. S;
Schunemann, H;
Mustafa, R. A;
Brignardello-Petersen, R.
BACKGROUND: Cervical cancer is the third most common gynecological malignancy in Saudi women with an estimated incidence rate of 1.9 cases per 100 000 women-years. More than 40% of cervical cancer cases are diagnosed at advanced stages due to lack of a routine screening program in Saudi Arabia. Thus, nat...
Evaluar la efectividad de las medidas preventivas para disminuir la aparición de nuevos casos de queratosis actínicas en la población general. o Evaluar la efectividad y la ocurrencia de eventos adversos asociados a los diferentes tratamientos farmacológicos y nofarmacológicos para el manejo de las ...
Neoplasias Cutâneas/diagnóstico,
Neoplasias Cutâneas/terapia,
Ceratose Actínica,
Raios Ultravioleta/efeitos adversos,
Protetores Solares/administração & dosagem,
Neoplasias Cutâneas/prevenção & controle,
Crioterapia,
Ácido Tricloroacético/administração & dosagem,
Fluoruracila/administração & dosagem,
Fotoquimioterapia,
Diclofenaco/administração & dosagem,
Abrasão Química,
Terapia a Laser
Cervical intraepithelial neoplasia (CIN) is a premalignant lesion that is diagnosed by histology as CIN1, CIN2, or CIN3. If left untreated, CIN2 or CIN3 (collectively referred to as CIN2+) can progress to cervical cancer. There are three principal treatments for CIN available in low- and middle-income co...
In 2008, cervical cancer was responsible for 275 000 deaths, of which about 88% occurred in low- and middle-income countries. Cervical cancer is the third most common cancer in women worldwide and the most common cancer in many low- and middle-income countries. Because it has a typically slow progression...
